Overview
AIM market data
Price History
AIM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.62 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -14,123.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.21 – $2.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7.9M · P/B 2.10 · P/S 84.30.
Company News
8-K filing — AIM ImmunoTech Inc. (AIM)SEC EDGAR · Aug 11, 2026, 12:40 PM
AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoYBenzinga · Aug 10, 2026, 12:38 PM
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical StudyBenzinga · Aug 3, 2026, 12:41 PM
AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026Benzinga · Jun 24, 2026, 12:40 PM
AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027Benzinga · Jun 18, 2026, 1:15 PM
AIM ImmunoTech Regains NYSE ComplianceBenzinga · Jun 15, 2026, 12:15 PM
AIM ImmunoTech Commences ~$2.65M Registered Direct Offering Of 2.554M Common Shares At $0.5189/ShareBenzinga · Jun 9, 2026, 1:40 PM
AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 SharesBenzinga · Jun 8, 2026, 8:15 PM
AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer TrialBenzinga · Jun 8, 2026, 12:45 PM
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response EffortsBenzinga · Jun 5, 2026, 6:30 PM